ALGN:NGS-Align Technology Inc. (USD)

EQUITY | Medical Devices | Nasdaq Global Select

Last Closing

USD 327.9

Change

+7.96 (+2.49)%

Market Cap

USD 7.53B

Volume

0.39M

Analyst Target

USD 325.93
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Align Technology Inc designs, manufactures and markets a system of clear aligner therapy, intra-oral scanners and CAD/CAM digital services used in dentistry, orthodontics, and dental records storage. Its segments are Clear Aligner and Scanners & Services.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-03-27 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

-13.67 (-9.91%)

USD 51.34B
BRKR Bruker Corporation

+0.38 (+0.47%)

USD 12.93B
SWAV Shockwave Medical Inc

+1.01 (+0.31%)

USD 12.34B
PODD Insulet Corporation

+2.02 (+1.23%)

USD 11.49B
MASI Masimo Corporation

+0.90 (+0.67%)

USD 7.14B
AXNX Axonics Modulation Technologie..

+0.15 (+0.23%)

USD 3.39B
IRTC iRhythm Technologies Inc

+0.64 (+0.58%)

USD 3.36B
QDEL Quidel Corporation

-0.05 (-0.13%)

USD 3.14B
LIVN LivaNova PLC

+0.43 (+0.78%)

USD 3.02B
IART Integra LifeSciences Holdings

-0.07 (-0.25%)

USD 2.64B

ETFs Containing ALGN

PINK Simplify Exchange Traded .. 4.64 % 0.00 %

-0.04 (-0.80%)

USD 0.12B
EKG First Trust Nasdaq Lux Di.. 4.10 % 0.00 %

+0.09 (+-0.80%)

USD 2.33M
UGCE 3.86 % 0.00 %

N/A

N/A
BMED BlackRock Future Health E.. 2.24 % 0.00 %

+0.08 (+-0.80%)

USD 4.21M
QQJE:CA Invesco ESG NASDAQ Next G.. 1.84 % 0.00 %

N/A

CAD 0.88M
QQJG Invesco ESG NASDAQ Next G.. 1.81 % 0.00 %

+0.18 (+-0.80%)

USD 5.25M
RSPH Invesco S&P 500® Equal.. 1.63 % 0.00 %

+0.12 (+-0.80%)

USD 1.02B
EQQJ:XETRA Invesco NASDAQ Next Gener.. 1.62 % 0.00 %

+0.51 (+-0.80%)

USD 0.05B
EQQJ:LSE Invesco NASDAQ Next Gener.. 1.59 % 0.00 %

+0.34 (+-0.80%)

USD 0.05B
EQQJ:SW Invesco NASDAQ Next Gener.. 1.57 % 0.00 %

+0.07 (+-0.80%)

N/A
EQJS:LSE Invesco NASDAQ Next Gener.. 1.55 % 0.00 %

+48.50 (+-0.80%)

USD 0.03B
DTEC ALPS Disruptive Technolog.. 1.19 % 0.00 %

+0.69 (+-0.80%)

USD 0.09B
HIBL Direxion Daily S&P 500® .. 1.04 % 0.00 %

+1.09 (+-0.80%)

USD 0.05B
XDED:XETRA Xtrackers S&P 500 Equal W.. 0.25 % 0.00 %

+0.77 (+-0.80%)

USD 6.30B
XDEW:SW Xtrackers S&P 500 Equal W.. 0.25 % 0.00 %

-0.64 (-0.80%)

USD 5.87B
EWSP:SW iShares S&P 500 Equal Wei.. 0.23 % 0.00 %

+0.03 (+-0.80%)

USD 1.19B
SPHB Invesco S&P 500® High Be.. 0.00 % 0.25 %

+0.73 (+-0.80%)

USD 0.58B
XHE SPDR® S&P Health Care Eq.. 0.00 % 0.35 %

+0.66 (+-0.80%)

USD 0.25B
XS2D:LSE Xtrackers S&P 500 2x Leve.. 0.00 % 0.00 %

+6.18 (+-0.80%)

USD 0.29B
DBPG:F Xtrackers - S&P 500 2x Le.. 0.00 % 0.00 %

+5.54 (+-0.80%)

USD 0.32B
DBPG:XETRA Xtrackers S&P 500 2x Leve.. 0.00 % 0.00 %

+6.32 (+-0.80%)

USD 0.32B
QQQJ Invesco NASDAQ Next Gen 1.. 0.00 % 0.00 %

+0.22 (+-0.80%)

USD 0.66B
QQQN VictoryShares Nasdaq Next.. 0.00 % 0.00 %

+0.33 (+-0.80%)

USD 0.02B

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 19.67% 81% B- 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 19.67% 81% B- 81% B-
Trailing 12 Months  
Capital Gain 7.08% 74% C 61% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.08% 74% C 58% F
Trailing 5 Years  
Capital Gain 15.32% 81% B- 62% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 15.32% 81% B- 56% F
Average Annual (5 Year Horizon)  
Capital Gain 25.89% 74% C 84% B
Dividend Return 25.89% 74% C 84% B
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 73.16% 40% F 22% F
Risk Adjusted Return 35.38% 84% B 71% C-
Market Capitalization 7.53B 99% N/A 97% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Devices) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 40.90 35% 19%
Price/Book Ratio 6.62 28% 17%
Price / Cash Flow Ratio 30.58 13% 10%
Price/Free Cash Flow Ratio 29.02 10% 8%
Management Effectiveness  
Return on Equity 12.31% 91% 81%
Return on Invested Capital 12.37% 90% 82%
Return on Assets 6.82% 95% 90%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector